How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?
Top Cited Papers
Open Access
- 10 February 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 163 (4), 675-693
- https://doi.org/10.1111/j.1476-5381.2011.01255.x
Abstract
Given that cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development, adverse drug reactions, and post‐approval withdrawal of medicines, the Medical Research Council Centre for Drug Safety Science hosted a workshop to discuss current challenges in determining, understanding and addressing ‘Cardiovascular Toxicity of Medicines’. This article summarizes the key discussions from the workshop that aimed to address three major questions: (i) what are the key cardiovascular safety liabilities in drug discovery, drug development and clinical practice? (ii) how good are preclinical and clinical strategies for detecting cardiovascular liabilities? and (iii) do we have a mechanistic understanding of these liabilities? It was concluded that in order to understand, address and ultimately reduce cardiovascular safety liabilities of new therapeutic agents there is an urgent need to: • Fully characterize the incidence, prevalence and impact of drug‐induced cardiovascular issues at all stages of the drug development process. • Ascertain the predictive value of existing non‐clinical models and assays towards the clinical outcome. • Understand the mechanistic basis of cardiovascular liabilities; by addressing areas where it is currently not possible to predict clinical outcome based on preclinical safety data. • Provide scientists in all disciplines with additional skills to enable them to better integrate preclinical and clinical data and to better understand the biological and clinical significance of observed changes. • Develop more appropriate, highly relevant and predictive tools and assays to identify and wherever feasible to eliminate cardiovascular safety liabilities from molecules and wherever appropriate to develop clinically relevant and reliable safety biomarkers.This publication has 67 references indexed in Scilit:
- Reducing QT liability and proarrhythmic risk in drug discovery and developmentBritish Journal of Pharmacology, 2010
- Value of non‐clinical cardiac repolarization assays in supporting the discovery and development of safer medicinesBritish Journal of Pharmacology, 2010
- The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidanceBritish Journal of Pharmacology, 2010
- A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery DiseaseThe New England Journal of Medicine, 2009
- Principles of Safety PharmacologyBritish Journal of Pharmacology, 2008
- International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug‐induced torsades de pointesBritish Journal of Pharmacology, 2008
- The failure of torcetrapib: what have we learned?British Journal of Pharmacology, 2008
- Shape Signatures: New Descriptors for Predicting Cardiotoxicity In SilicoChemical Research in Toxicology, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibitionCellular Signalling, 2007